JUNE 28 2023 Webinar on the New FDA Approved Drug Ritlecitinib (Litfulo)

Join Me June 28th as We Discuss the New FDA Approval of Ritlecitinib (Litfulo) for Alopecia Areata

On Jun 23, 2023 the US Food and Drug Administration approved Ritlecitinib (Litfulo) for the treatment of severe alopecia areata. This marks the second drug approved for severe forms of alopecia areata and comes just 12 months (actually 12 months and 10 days) after the first drug (baricitinib) was FDA approved.

Ritlecitinib (now to be marketed as Litfulo) is approved for individuals 12 and over with severe alopecia. Similar to baricitinib, the drug does not help everyone but does help about 25 % of patients achieve fairly good regrowth after six months of using the drug. The drug will be needed lifelong for most patients.

On Wednesday June 28, 2023, I will host a webinar discussing ritlecitinib in more depth. I’ll review how well it works, the potential side effects, the unknown issues that still exist with the drug and review how it compares to baricitinib. We’ll start 5 pm PST (8 pm EST). Registration required.

If you miss it, we’ll post the recording at a later date on our DonovanMedical Youtube channel.

Register for the webinar at donovanmedical.com/webinars or using the link below.

See you then.